Study of Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes

Trial ID or NCT#

NCT03558386

Status

not recruiting iconNOT RECRUITING

Purpose

This is a multi-center, Phase II, cross-sectional study comparing quality of life (QOL) as assessed by patient-reported outcomes (PROs) in older (≥65 years) adults vs younger (55-64 years) undergoing allogeneic hematopoietic cell transplantation (HCT) for myelodysplastic syndromes (MDS).

Official Title

A Multi-Center, Phase II Cross-sectional Study Investigating Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: a Companion Study to the CIBMTR 10-CMSMDS-1-Approved Expanded Access Study

Eligibility Criteria

Ages Eligible for Study: Older than 55 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. In order to be eligible to participate on this study, an individual must meet all of the following criteria:
    1. 1. Underwent an allogeneic HCT for MDS on the 10-CMSMDS-1 protocol2. Prior consent to research and future contact by the CIBMTR3. Ability to provide RCI BMT protocol 17-ePRO signed and dated informed consent form (ICF)4. Age ≥55 years at time of transplant5. Fluent in English or Spanish6. Greater than 6 months post-HCT
Exclusion Criteria:
  1. An individual who meets any of the following criteria will be excluded from participation on this study.
    1. 1. No access to an internet browser or email account2. Within 6 months of first HCT for MDS on the 10-CMSMDS-1 protocol

Investigator(s)

Lori Muffly
Lori Muffly
Hematologist, Blood and marrow transplant specialist, Blood and marrow transplant specialist, Hematologist-Oncologist
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Contact us to find out if this trial is right for you.

Contact

Michelle Chin, MS
650-721-4183